 Research Plan Synopsis - Trial Design: Randomised, stratified multicentre phase IIIII study. The study will proceed in 2 phases, initially a randomised phase II stage evaluating safety after 60 patients approx 20 per arm and 150 patients approx 50 per arm have completed at least 6 weeks treatment. This will continue with a randomised phase III stage evaluating activity, toxicity and quality of life measures. 